Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating ...
Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Provides Update on Commercial Manufacturing
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Greenwich LifeSciences gains after GP2 commercial manufacturing update
Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2. Read more here.
Greenwich LifeSciences announces activation of Phase 3 trial in Poland
Greenwich LifeSciences (GLSI) announced the activation of clinical sites in Poland in tis Phase III clinical trial, FLAMINGO-01, which is ...
Nasdaq8d
Greenwich LifeSciences Receives EMA Approval for Expanded Clinical Trial Sites in Europe for FLAMINGO-01 Study
Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...
Morningstar10d
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...
manilatimes15d
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Mena FN9d
Greenwich Lifesciences Approved To Add Additional Sites To FLAMINGO-01 In Europe
(MENAFN- GlobeNewsWire - Nasdaq) STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage ...